Clinical Trial Update: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of AZD8835 to assess safety and pharmacokinetics in patients with advanced solid tumors, including breast cancer subtypes ER-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• AZD8835

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 - | Phase 1 | Status: COMPLETED